Comparison of pheochromocytomas and abdominal and pelvic paragangliomas with head and neck paragangliomas

Endocrine Practice

Volumn 15, Issue 3, 2009, Pages 194-202

  Al Harthy, Mohamed ^a   Al Harthy, Saud ^a   Al Otieschan, Abdullah ^b   Velagapudi, Suresh ^b   Alzahrani, Ali S ^a,b  

^a Section of Endocrinology   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CATECHOLAMINE; OCTREOTIDE;

ABDOMINAL TUMOR; ADULT; ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HEAD AND NECK TUMOR; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PARAGANGLIOMA; PELVIS TUMOR; PHEOCHROMOCYTOMA; RETROSPECTIVE STUDY; SWEATING; TUMOR REGRESSION; TUMOR VOLUME;

EID: 67649221727     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.15.3.194     Document Type: Article

References (25)

1. Lack EE. Tumors of the Adrenal Gland and Extra-Adrenal Paraganglia. Atlas of Tumor Pathology. Berlin: Springer, 2000: 38-48.
2. Manger WM, Gifford RW, eds. The Clinical and Experimental Pheochromocytoma. 2nd ed. Malden, MA: Blackwell Science, 1996.
3. Erickson D, Kudva YC, Ebersold MJ, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86: 5210-5216.
4. Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001;134:315-329.
5. Neumann HP, Pawlu C, Peczkowska M, et al; European- American Paraganglioma Study Group. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations [erratum in JAMA. 2004;292:1686]. JAMA. 2004;292:943-951.
6. Sajid MS, Hamilton G, Baker DM; Joint Vascular Research Group. A multicenter review of carotid body tumour management. Eur J Vasc Endovasc Surg. 2007;34: 127-130.
7. Wängberg B, Muth A, Khorram-Manesh A, et al. Malignant pheochromocytoma in a population-based study: survival and clinical results. Ann N Y Acad Sci. 2006;1073: 512-516.
8. Stenström G, Svärdsudd K. Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand. 1986;220:225-232.
9. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1983;58:802-804.
10. Mannelli M, Simi L, Gaglianò MS, et al. Genetics and biology of pheochromocytoma. Exp Clin Endocrinol Diabetes. 2007;115:160-165.
11. McNicol AM. Histopathology and immunohistochemistry of adrenal medullary tumors and paragangliomas. Endocr Pathol. 2006;17:329-336.
12. Bhatia KS, Ismail MM, Sahdev A, et al. 123I- metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf). 2008;69:181-188.
13. Neumann HP, Bausch B, McWhinney SR, et al; Freiburg-Warsaw-Columbus Pheochromocytoma Study Group. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002;346:1459-1466.
14. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol. 2005;23:8812-8818.
15. Gimenez-Roqueplo AP, Lehnert H, Mannelli M, et al. Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf). 2006;65:699-705.
16. Pacak K, Eisenhofer G, Ahlman H, et al; International Symposium on Pheochromocytoma. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007;3:92-102.
17. Ahlman H. Malignant pheochromocytoma: state of the field with future projections. Ann N Y Acad Sci. 2006;1073: 449-464.
18. Schlumberger M, Gicquel C, Lumbroso J, et al. Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases. J Endocrinol Invest. 1992;15:631-642.
19. Scott HW Jr, Halter SA. Oncologic aspects of pheochromocytoma: the importance of follow-up. Surgery. 1984;96:1061-1066.
20. Goldstein RE, O'Neill JA Jr, Holcomb GW 3rd, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999;229:755-764.
21. Nativ O, Grant CS, Sheps SG, et al. The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma. Cancer. 1992;69:2683-2687.
22. Salmenkivi K, Arola J, Voutilainen R, et al. Inhibin/activin betaB-subunit expression in pheochromocytomas favors benign diagnosis. J Clin Endocrinol Metab. 2001;86: 2231-2235.
23. Linden MD, Ma CK, Kubus J, Brown RD, Zarbo RJ. Ki-67 and proliferating cell nuclear antigen tumor proliferative indices in DNA diploid colorectal adenocarcinomas. Correlation with histopathologic characteristics and cell cycle analysis with two-color DNA flow cytometry. Am J Clin Pathol. 1993;100:206-212.
24. Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Keiser HR, Israel MA. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. J Clin Oncol. 1989;7:1720-1725.
25. Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer. 2007;14: 569-585.